CL2013003563A1 - Compuestos derivados de amidas del ácido gambógico y sus sales; composición farmacéutica que los comprende, útil en el tratamiento del glioblastoma. - Google Patents

Compuestos derivados de amidas del ácido gambógico y sus sales; composición farmacéutica que los comprende, útil en el tratamiento del glioblastoma.

Info

Publication number
CL2013003563A1
CL2013003563A1 CL2013003563A CL2013003563A CL2013003563A1 CL 2013003563 A1 CL2013003563 A1 CL 2013003563A1 CL 2013003563 A CL2013003563 A CL 2013003563A CL 2013003563 A CL2013003563 A CL 2013003563A CL 2013003563 A1 CL2013003563 A1 CL 2013003563A1
Authority
CL
Chile
Prior art keywords
glioblastoma
salts
useful
treatment
pharmaceutical composition
Prior art date
Application number
CL2013003563A
Other languages
English (en)
Inventor
Bjorn Scheffler
Martin Glas
Matthias Simon
Sabine Gogolok
Daniel Trageser
Roman Reinartz
Anja Wieland
Original Assignee
Univ Bonn Rheinische Friedrich Wilhelms
Life And Brain Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bonn Rheinische Friedrich Wilhelms, Life And Brain Gmbh filed Critical Univ Bonn Rheinische Friedrich Wilhelms
Publication of CL2013003563A1 publication Critical patent/CL2013003563A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/06Peri-condensed systems
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2013003563A 2011-06-15 2013-12-12 Compuestos derivados de amidas del ácido gambógico y sus sales; composición farmacéutica que los comprende, útil en el tratamiento del glioblastoma. CL2013003563A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161497215P 2011-06-15 2011-06-15

Publications (1)

Publication Number Publication Date
CL2013003563A1 true CL2013003563A1 (es) 2014-06-06

Family

ID=46319762

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003563A CL2013003563A1 (es) 2011-06-15 2013-12-12 Compuestos derivados de amidas del ácido gambógico y sus sales; composición farmacéutica que los comprende, útil en el tratamiento del glioblastoma.

Country Status (13)

Country Link
US (1) US9573960B2 (es)
EP (1) EP2721035B1 (es)
JP (1) JP6228113B2 (es)
CN (1) CN103764659A (es)
AU (1) AU2012268984B2 (es)
BR (1) BR112013032360A2 (es)
CA (1) CA2838945A1 (es)
CL (1) CL2013003563A1 (es)
IL (1) IL229767A0 (es)
MX (1) MX340816B (es)
RU (1) RU2014101070A (es)
WO (1) WO2012172069A1 (es)
ZA (1) ZA201309365B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014023329A1 (en) 2012-08-06 2014-02-13 Life And Brain Gmbh Niclosamide and its derivatives for use in the treatment of solid tumors
US10905665B2 (en) 2015-06-24 2021-02-02 Duke University Chemical modulators of signaling pathways and therapeutic use
WO2017023277A1 (en) * 2015-07-31 2017-02-09 Swedish Health Services Methods and compositions for characterization of glioblastoma multiforme tumors and cancer stem cells
EP3349774A4 (en) * 2015-09-15 2019-03-27 Swedish Health Services METHOD AND COMPOSITE SHEETS FOR CHARACTERIZING GLOBALBLASTOMA MULTIFORM TUMORS AND CANCER STEM CELLS THEREOF
CN105802928A (zh) * 2016-03-30 2016-07-27 苏州偲聚生物材料有限公司 用于检测血清中mgmt抗体的多肽,检测器件和检测试剂盒
CN105796549A (zh) * 2016-04-22 2016-07-27 中国医学科学院基础医学研究所 藤黄酰胺用于制备治疗人神经胶质瘤的药物的用途
CN107475213A (zh) * 2016-06-08 2017-12-15 中国科学院苏州纳米技术与纳米仿生研究所 用于检测血清中mgmt抗体的多肽,检测器件和检测试剂盒
US11311606B2 (en) 2018-03-13 2022-04-26 Georgetown University Enhancing chemotherapy in medulloblastoma and glioblastoma with high basal p53 levels
CN110433154A (zh) * 2019-08-12 2019-11-12 昆明理工大学 藤黄酸的新用途
WO2023183463A1 (en) * 2022-03-23 2023-09-28 University Of Cincinnati Methods of potentiating temozolomide activity against glioblastoma cells
CN117538458B (zh) * 2024-01-09 2024-03-29 中国医学科学院北京协和医院 同时定量分析14种单糖/二糖的液相色谱串联质谱分析方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2864100A (en) * 1999-02-01 2000-08-18 Cytovia, Inc. Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products
AU2746000A (en) * 1999-02-01 2000-08-18 Cytovia, Inc. Gambogic acid, analogs and derivatives as activators of caspases and inducers ofapoptosis
US6462041B1 (en) * 1999-05-21 2002-10-08 Cytovia, Inc. Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis
JP3904364B2 (ja) 2000-03-03 2007-04-11 独立行政法人科学技術振興機構 抗マラリア活性を有する新規化合物
EP1300403A1 (en) * 2001-10-02 2003-04-09 Aventis Pharma S.A. Process for the manufacture of hypoxyxylerone derivatives
WO2008148008A1 (en) * 2007-05-23 2008-12-04 Emory University High throughput bioassay for identifying selective trka receptor agonists, and gambogic amide, a selective trka agonist with neuroprotective activity
CN101289482B (zh) * 2007-09-29 2011-08-31 辽宁利锋科技开发有限公司 藤黄酸苷衍生物和类似物及其制备方法和用途
PA8851101A1 (es) * 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol

Also Published As

Publication number Publication date
NZ618170A (en) 2015-04-24
MX340816B (es) 2016-07-26
CA2838945A1 (en) 2012-12-20
EP2721035B1 (en) 2018-06-13
JP2014517025A (ja) 2014-07-17
EP2721035A1 (en) 2014-04-23
WO2012172069A1 (en) 2012-12-20
ZA201309365B (en) 2015-11-25
MX2013014708A (es) 2014-08-18
BR112013032360A2 (pt) 2017-06-13
IL229767A0 (en) 2014-01-30
CN103764659A (zh) 2014-04-30
US20150148390A1 (en) 2015-05-28
RU2014101070A (ru) 2015-07-20
AU2012268984B2 (en) 2016-07-14
JP6228113B2 (ja) 2017-11-08
US9573960B2 (en) 2017-02-21

Similar Documents

Publication Publication Date Title
CL2013003563A1 (es) Compuestos derivados de amidas del ácido gambógico y sus sales; composición farmacéutica que los comprende, útil en el tratamiento del glioblastoma.
SMT201700003B (it) Didropiridoni come inibitori del fattore xia
CL2014003136A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
DK3192501T3 (da) Topisk farmaceutisk sammensætning baseret på semifluorerede alkaner
BR112013023156A2 (pt) artigos para cuidados pessoais
DK2920149T3 (da) 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf
DK2694038T3 (da) Farmaceutisk sammensætning
BR112015002738A2 (pt) composto , e , composição farmacêutica
DK2875005T3 (da) N-(3-heteroarylaryl)-4-arylarylcarboxamider og analoger som hedgehog pathway inhibitorer, og anvendelse deraf
CL2014002954A1 (es) Composicion farmaceutica que contiene anticuerpos anti-il-23p19 y sus usos.
BR112014009889A2 (pt) compostos dissubstituídos, compostos e composição farmacêutica
CR20140263A (es) Composicion herbicida que contiene acido de 4-amino-3-cloro-6-(-4-cloro-2-fluor-3-metoxifenil) piridina-2-carboxilico, o los derivados del mismo y fluroxipir, o los derivados del mismo
DK2773633T3 (da) Heterocykliske forbindelser, medikamenter indeholdende forbindelserne, anvendelse deraf og fremgangsmåder til fremstilling deraf.
CR20150211A (es) Compuestos diméricos
DK2897594T3 (da) Farmaceutisk sammensætning
CL2014002978A1 (es) Combinaciones farmacéuticas que contienen un inhibidor de 11-beta-hidroxiesteroide dehidrogenasa para el tratamiento de trastornos metabólicos
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
DK2854765T3 (da) Farmaceutisk pemetrexed-opløsning
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
CL2014000484A1 (es) Compuestos derivados del acido pirrolidin-3-il-acetico; composicion farmaceutica que los comprende y uso en el tratamiento de la enfermedad inflamatoria del intestino.
FI20116047L (fi) Menetelmä terveyskortin hallinnoimiseksi
BR112013022907A2 (pt) composição farmacêutica